Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics Collaboration to Explore Clinical Uses of Personal Genetics and TamoxifenStrategic Research Agreement • October 23rd, 2007 • Laboratory Corp of America Holdings • Services-medical laboratories
FRANKLIN LAKES, NJ and BURLINGTON, NC, October 22, 2007 – Medco Health Solutions Inc. (NYSE: MHS) and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced a strategic research agreement today to advance the field of pharmacogenomics, an emerging science integrating genetics and drug treatment that is leading the way toward personalized medicine. The research effort, which will be centered on tamoxifen, is the latest in a rapidly growing field of studies linking individual genetics to the safety and efficacy of specific prescription drugs. Genotyping for the study will be performed using the FDA-cleared Roche AmpliChip® CYP450 test.
